The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients

  • Mezquita L
  • Auclin E
  • Charrier M
  • et al.
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background: Derived NLR (neutrophils/(leucocytes-neutrophils) ratio) and lactate dehydrogenase (LDH) have been correlated to immune checkpoint inhibitors (ICI) benefit in melanoma. We tested whether baseline dNLR and LDH, as a score, could have the same role in advanced NSCLC patients. Methods: Baseline dNLR and LDH were retrospectively collected in 466 patients treated with ICI from Nov. 2013 to Jan. 2017, in a training cohort (N=161) and a validation cohort (N=305) from 8 European centers. As a control, a cohort (N=162) treated only with chemotherapy between Nov. 2012 and Jul. 2016 from 2 centers. The primary endpoint was overall survival (OS), and secondary endpoints were progression free survival (PFS) and disease control rate (DCR). Results: In the immunotherapy cohort, 301 patients (65%) were males, 422 (90%) smokers and 401 (87%) with PS ≥1, with median age 63 years; 270 (58%) had adenocarcinoma and 159 (34%) squamous; 85 (18%) were KRASmut, 19 (4%) EGFRmut and 6 (1%) ALK positive. PDL1 was ≥ 1% by immunohistochemistry in 96 (74%), negative in 33 (26%) and unknown in 337 patients. The median of prior lines was 1 (0- 11). In the training cohort, the median PFS and OS were 3months (m) [2-4] and 10m [8-13]. dNLR>3 and LDH> Upper Limit of Normal (ULN) were independent factors for OS (HR 2.22, 95% CI 1.23-4.01; HR 2,51, 1.32-4.76, respectively). According to dNLR>3 and LDH>ULN, LIPI categorized 3 groups (good: 0 factor, intermediate: 1 factor, poor: 2 factors), which correlated with outcome in both cohorts. Median OS for good, intermediate, and poor was 34m, 10m and 3m, respectively (p=0.0001). The PFS and DCR were also correlated (p=0.001, p=0.005). Same results were observed in the validation cohort for OS (p=0.004), PFS and DCR (both p=0.005), but not in the chemotherapy cohort for both factors analyzed. Conclusions: Baseline LIPI, combining dNLR>3 and LDH>ULN, predicts the resistance to ICI acording to OS, PFS and DCR, but it is not correlated with the efficacy of chemotherapy, suggesting LIPI as a predictive score in ICI treatment.

Cite

CITATION STYLE

APA

Mezquita, L., Auclin, E., Charrier, M., Ferrara, R., Remon Masip, J., Planchard, D., … Besse, B. (2017). The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients. Annals of Oncology, 28, v473. https://doi.org/10.1093/annonc/mdx380.029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free